

# VACCINE INVESTMENT STRATEGY: SHORT LIST

---

BOARD MEETING

**Wilson Mok**


6-7 June 2018, Geneva, Switzerland



Reach every child

[www.gavi.org](http://www.gavi.org)

# VIS 2018 timeline and process



# Evaluation criteria and indicators for vaccines for endemic disease prevention

Criteria		Indicators	Criteria		Indicators	
Ranking criteria:	Health impact	Total future deaths averted 2020-2035, and per 100,000 vaccinated	Secondary criteria:	Other impact	Total US deaths averted 2020-2035, and per 100,000 vaccinated	
		Total future cases averted 2020-2035, and per 100,000 vaccinated			Total DALYs averted 2020-2035, and per 100,000 vaccinated	
	Value for money	Vaccine procurement cost per death averted		Gavi comparative advantage	Implementation feasibility	Vaccine procurement cost per DALY averted
		Vaccine procurement cost per case averted				Degree of vaccine market challenges
	Equity and social protection impact	Disproportionate impact of disease on vulnerable groups				Alternate interventions
		Special benefits of vaccination for women and girls		Ease of supply chain integration		
Economic impact	Direct medical cost averted	Financial implications:	Vaccine cost	Need for health care worker behaviour change		
	Indirect cost averted			Operational cost		
Global health security impact	Epidemic potential of disease	Additional implementation costs	Additional costs for introduction	Feasibility of vaccination time point		
	Impact of vaccination on antimicrobial resistance (AMR)			Acceptability in target population		
				Long-term financial implications		
				Optimal use of current and future alternative interventions (prevention and treatment)		
				<i>No specific indicator – evaluated case-by-case</i>		
				Total procurement cost to Gavi and countries, 2020-2035		
				Incremental in-country operational costs per vaccinated person		

# Evaluation of vaccines conducted consultatively with technical partners and in-country stakeholders

## Demand Forecasting

- Vaccine products
- Vaccination strategy
- Schedule/dosing
- Delivery strategy
- Target population
- Country introduction
- Coverage

## Impact Modelling

- Burden of disease
- Case fatality rate
- Efficacy
- Duration of protection

## Price Forecasting

- Products
- Supplier projections
- Price projections

## Other quant. analyses

- Procurement cost
- Operational costs
- Value for money
- Economic impact: cost of illness
- Global burden of disease

## Qualitative analyses

- Epidemic potential
- Impact on AMR
- Implementation feasibility
- Vaccination policy
- Other qualitative input

BILL & MELINDA  
GATES foundation



LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



WHO



UNIVERSITY OF  
CAMBRIDGE



JOHNS HOPKINS  
UNIVERSITY

Imperial College  
London

University  
of Antwerp



# Board consultations informed prioritisation methodology

---




## Shortlisting approach

Supportive of having multiple options



## Ranking criteria

Health impact: 40%  
Value for money: 20%  
Equity: 15%  
Economic impact: 10%  
Global health security: 15%



## Secondary criteria

Consensus to use to adjust ranking



## Existing investments

Mixed opinion on prioritising expansion of existing investments over new ones




## Total vs. relative

Preference for total impact vs. per 100k vaccinated

Source: Consultations with Gavi Board members representing 17 constituencies/seats in February 2018

# Ranking based on Board member criteria weighting

Total Points (out of 100)<sup>1</sup>



■ Health impact 
 ■ Value for money 
 ■ Equity and social protection 
 ■ Economic impact 
 ■ Global health security

1. Maximum 40pts for health impact (30pts for total deaths averted, 10pts for deaths averted per 100k), 20pts for value for money (cost per death averted), 15pts for equity and social protection impact, 10pts for economic impact and 15pts for global health security  
 Note: Malaria not up for investment decision. Used as comparator with Health impact and economic impact based on high-level estimates

# Four questions guide the assessment of potential investments in epidemic preparedness and response

---

## Disease Risk & Burden

1. Is the epidemic potential of disease sufficient to prioritise a stockpile or similar investment?

## Vaccine Impact & Feasibility

2. Would the vaccine be feasible to use and impactful as part of epidemic preparedness and response?


## Fit for Gavi & Partners

3. What is Gavi's comparative advantage and how can Gavi's expertise contribute to the funding and delivery of this vaccine?

## Financial Implications

4. What is the appropriate scale of the stockpile (or related intervention) and what would be the financial implications of an investment?

# 'Living assessments' will be developed for relevant vaccines until an investment case is needed



**VACCINES UNDER CONSIDERATION (to be refreshed)**

*Examples from WHO R&D Blueprint priority pathogens: Lassa fever, MERS, Nipah, Rift Valley Fever, etc.*


*Indicative list:*

- Hepatitis E
- Ebola 2<sup>nd</sup> gen
- Chikungunya
- Zika

**Pandemic Flu**

Brought to PPC & Board Oct/Nov 2018

# Several options to support pandemic flu preparedness are emerging as most suitable for Gavi to consider



# Next steps for October/November 2018 PPC/Board

## Programme design

- Programme / support options
- Implementation requirements and feasibility

## Financial implications

- Procurement costs (Gavi and countries)
- Operational costs, including for new platforms
- Financial implications for countries

## Consultations

- In-country, technical partners, experts, Board
- Vaccine preferences, programme design, implementation

## Portfolio considerations

- Synergies and trade-offs across potential investments and with current portfolio
- Alignment / implications for Gavi's current model
- Continue linking with ongoing 5.0 development

## FOR DECISION: New vaccine investments

- Shortlisted vaccines for endemic disease prevention
- Pandemic influenza
- IPV post-2020

# Recommendation

---

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

- a) **Approve** narrowing the choice of possible vaccine investment options for further analysis within the endemic disease prevention category of the Vaccine Investment Strategy 2018 to meningitis (multivalent conjugate); hepatitis B birth dose; cholera; DTP boosters; RSV; rabies;
- b) **Approve** the evaluation criteria for potential new investments in vaccines for epidemic preparedness and response and the approach for applying the criteria towards living assessments and investment cases as further described in Figures 2 and 3;
- c) **Request** the Secretariat, in consultation with WHO and other experts, to develop an investment case for Gavi to support pandemic influenza preparedness for PPC and Board review.

**Thank you**

---



[www.gavi.org](http://www.gavi.org)